Studies Link Widely Used Diabetes, Weight-Loss Meds with Increased Risk of Stomach Paralysis. Popular diabetes and weight loss medications like Ozempic and Wegovy have been linked to an increased risk of developing stomach paralysis, according to new studies.
Understanding Stomach Paralysis
Stomach paralysis, also known as gastroparesis, weakens the stomach muscles, leading to food remaining in the main digestive organ for prolonged periods.
This condition can cause significant discomfort and digestive issues, impacting the quality of life of those affected.
Medications in Focus: Wegovy and Ozempic
Wegovy, approved by the US Food and Drug Administration (FDA) for weight management, and Ozempic, approved for managing blood sugar levels in patients with type 2 diabetes, have been at the center of these studies.
Both medications are injections containing semaglutide, a protein similar to the hormone glucagon-like peptide-1 (GLP-1).
GLP-1 is released in response to meal intake, promoting insulin production and helping regulate blood sugar levels.
Although Ozempic is not FDA-approved for weight loss, it is sometimes prescribed off-label for this purpose due to its effectiveness in promoting weight loss.
Gastrointestinal Side Effects
While GLP-1 receptor agonists, or GLP-1 analogues, are known to cause gastrointestinal side effects such as nausea, vomiting, and diarrhea, recent studies presented at Digestive Disease Week 2024, held from May 18-21 in Washington DC, reveal more serious concerns.
These include less common but severe side effects such as stomach paralysis (gastroparesis), ileus (a temporary lack of movement in the intestines), and acute pancreatitis.
Key Study Findings
University of Kansas Study
Researchers from the University of Kansas analyzed data from 1.85 lakh patients with diabetes or obesity who were prescribed GLP-1 analogues between December 1, 2021, and November 30, 2022. The findings were alarming:
- Gastroparesis: 0.53% of the patients developed this condition, with the risk increasing by 66%.
- Cholecystitis: 0.55% of patients developed inflammation of the gallbladder, with a 28% increased risk.
- Drug-Induced Pancreatitis: 0.04% of patients experienced this severe condition, with the risk increasing by over 350%.
- Nausea and Vomiting: 9% of the patients had a significantly higher incidence of these symptoms.
- Gastro-Oesophageal Reflux Disease (GERD): 7.5% showed a higher incidence of GERD, where stomach contents move up the oesophagus.
The study’s authors concluded that the use of GLP-1 agonists in patients with diabetes and obesity is associated with a range of gastrointestinal side effects, necessitating further scrutiny and caution in their use.
Cleveland Clinic Study
Another significant study assessed the risk of gastroparesis in patients with type 2 diabetes treated with GLP-1 receptor agonists. This study included over 3.36 lakh patients in two cohorts: one receiving the medication and the other not.
- The study found an increased risk of gastroparesis at various intervals (6, 9, 12, 18, and 24 months) for those prescribed GLP-1 RAs.
- The odds ratio for developing gastroparesis significantly increased from 6 months through 24 months after controlling for various risk factors.
Mayo Clinic Minnesota Study
A third study by the Mayo Clinic in Minnesota examined information from almost 80,000 patients who had received GLP-1 RA prescriptions. The researchers discovered that:
- Gastroparesis Symptoms: 18% (about 14,660) of these patients developed at least one new gastrointestinal symptom suggestive of gastroparesis.
- Gastric Emptying Scintigraphy: About 700 of the affected patients underwent this diagnostic procedure, which assesses the stomach’s ability to empty. Approximately one-third of this group was confirmed to have gastroparesis.
Implications and Next Steps
The findings from these studies underscore the need for healthcare professionals to monitor patients on GLP-1 receptor agonists closely.
The significant increase in the risk of severe gastrointestinal conditions such as gastroparesis, cholecystitis, and pancreatitis calls for a balanced approach in prescribing these medications.
Patients should be informed about the potential risks and encouraged to report any unusual symptoms immediately.
Further research is essential to fully understand the long-term impacts of these medications and to develop strategies to mitigate their adverse effects.
Conclusion
The recent studies highlight a crucial need for vigilance in the use of diabetes and weight loss medications like Ozempic and Wegovy.
While effective in managing blood sugar levels and promoting weight loss, the potential for severe gastrointestinal side effects warrants a cautious approach to their prescription and use.
The information is collected from Healthline and MSN.
